Literature DB >> 8052351

A case of lipoprotein glomerulopathy successfully treated with probucol.

M Amenomori1, M Haneda, J Morikawa, I Nishigaki, S Maeda, H Hidaka, R Kikkawa, Y Shigeta.   

Abstract

A 54-year-old woman presented proteinuria and severe hyperlipoproteinemia, She had type III hyperlipoproteinemia with the phenotype E2/2. Renal biopsy specimen revealed lipoprotein thrombi within the glomerular capillary lumina without tubulointerstitial lesion and deposition of IgA in the mesangium and peripheral capillary loops, indicating lipoprotein glomerulopathy with IgA nephropathy. Treatment with probucol resulted in the improvement of both hyperlipoproteinemia and proteinuria with the disappearance of the lipoprotein thrombi in the glomerular capillary without any change in the mesangial IgA deposition. The data suggest that probucol may be effective against the early stage of lipoprotein glomerulopathy with less lipoprotein thrombi and without tubulointerstitial damage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8052351     DOI: 10.1159/000187897

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

1.  Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.

Authors:  Hiroko Hamatani; Keiju Hiromura; Keiko Kobatake; Hiroaki Yoshida; Satsuki Kobayashi; Naohiro Yoneda; Ken Kayakabe; Takayuki Matsumoto; Takashi Kuroiwa; Kazue Ueki; Yoshihisa Nojima
Journal:  Clin Exp Nephrol       Date:  2010-09-15       Impact factor: 2.801

2.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 3.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

4.  Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.

Authors:  Akira Matsunaga; Masayuki Furuyama; Taeko Hashimoto; Kentaro Toyoda; Daisuke Ogino; Kiyoshi Hayasaka
Journal:  Clin Exp Nephrol       Date:  2009-07-15       Impact factor: 2.801

Review 5.  Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.

Authors:  Miho Karube; Kimimasa Nakabayashi; Yasunori Fujioka; Ken Yoshihara; Akira Yamada; Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

6.  Clinicopathological analysis of IgA nephropathy combined with other glomerular diseases.

Authors:  Lei Jiang; Bao Dong; Yu Yan; Shuying Zheng; Yanan Hu; Li Zuo; Hongxia Shi
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

7.  Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature.

Authors:  Kunio Kawanishi; Anri Sawada; Ayami Ochi; Takahito Moriyama; Michihiro Mitobe; Toshio Mochizuki; Kazuho Honda; Hideaki Oda; Toshio Nishikawa; Kosaku Nitta
Journal:  Case Rep Nephrol Urol       Date:  2013-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.